Skip to content

MOLN

Molecular Partners AG

NASDAQ · Healthcare · Biotechnology · CH

$3.20
+3.40%
Ask drillr

Forward multiples

Based on analyst estimates

P/E forward
—
P/E 2026E
—
P/E 2027E
—
P/E 2028E
—
P/S forward
—

Trailing multiples

Trailing twelve months

P/E TTM
—
PEG TTM
—
Price / book
1.98x
Price / sales
—
Price / cash flow
-2.03x

Enterprise value

Enterprise value
$55.5M
EV / sales
—
EV / EBITDA
-0.87x
EV / EBIT
-0.83x
Market cap
$122.4M

Trailing, forward and enterprise-value multiples for the requested listing · Data as of Sep 1, 2026